Peter O'Donnell to Urinary Bladder Neoplasms
This is a "connection" page, showing publications Peter O'Donnell has written about Urinary Bladder Neoplasms.
Connection Strength
3.988
-
Preferred Treatment Sequencing for Metastatic Urothelial Carcinoma (mUC) in the Era of Perioperative and First-Line (1L) Checkpoint Inhibitor: Results From a National Survey of Genitourinary Oncologists. Clin Genitourin Cancer. 2026 Mar; 24(2):102487.
Score: 0.685
-
Patient-reported outcomes and inflammatory biomarkers in patients with locally advanced/metastatic urothelial carcinoma treated with durvalumab in phase 1/2 dose-escalation study 1108. Cancer. 2020 01 15; 126(2):432-443.
Score: 0.445
-
Case Report of a Rare Presentation of Urothelial Carcinoma With Gastric Metastasis. Clin Genitourin Cancer. 2016 Feb; 14(1):e111-4.
Score: 0.337
-
Bladder cancer pharmacogenomics: recent insights and future perspectives. Pharmacogenomics. 2012 Nov; 13(14):1553-6.
Score: 0.275
-
Editorial comment. Urology. 2011 Jan; 77(1):165-6.
Score: 0.243
-
Perioperative Enfortumab Vedotin and Pembrolizumab in Bladder Cancer. N Engl J Med. 2026 Apr 02; 394(13):1257-1269.
Score: 0.173
-
HER2 and urothelial carcinoma: current understanding and future directions. Nat Rev Urol. 2026 02; 23(2):110-132.
Score: 0.167
-
Efficacy and safety of pembrolizumab in patients with advanced urothelial carcinoma deemed potentially ineligible for platinum-containing chemotherapy: Post hoc analysis of KEYNOTE-052 and LEAP-011. Cancer. 2025 Jan 01; 131(1):e35601.
Score: 0.158
-
Bladder-Preserving Trimodality Therapy With Capecitabine. Clin Genitourin Cancer. 2024 04; 22(2):476-482.e1.
Score: 0.150
-
Atezolizumab plus chemotherapy versus placebo plus chemotherapy in untreated locally advanced or metastatic urothelial carcinoma (IMvigor130): final overall survival analysis results from a randomised, controlled, phase 3 study. Lancet Oncol. 2024 01; 25(1):29-45.
Score: 0.149
-
Efficacy and safety of pembrolizumab in metastatic urothelial carcinoma: results from KEYNOTE-045 and KEYNOTE-052 after up to 5 years of follow-up. Ann Oncol. 2023 03; 34(3):289-299.
Score: 0.139
-
Collaborative study from the Bladder Cancer Advocacy Network for the genomic analysis of metastatic urothelial cancer. Nat Commun. 2022 11 04; 13(1):6658.
Score: 0.138
-
Putative Biomarkers of Clinical Benefit With Pembrolizumab in Advanced Urothelial Cancer: Results from the KEYNOTE-045 and KEYNOTE-052 Landmark Trials. Clin Cancer Res. 2022 05 13; 28(10):2050-2060.
Score: 0.133
-
Health-related Quality of Life of Patients with Locally Advanced or Metastatic Urothelial Cancer Treated with Enfortumab Vedotin after Platinum and PD-1/PD-L1 Inhibitor Therapy: Results from Cohort 1 of the Phase 2 EV-201 Clinical Trial. Eur Urol. 2022 05; 81(5):515-522.
Score: 0.131
-
EZR-ROS1 fusion renal cell carcinoma mimicking urothelial carcinoma: report of a previously undescribed gene fusion in renal cell carcinoma. Virchows Arch. 2022 Feb; 480(2):487-492.
Score: 0.125
-
CD8 lymphocytes in tumors and nonsynonymous mutational load correlate with prognosis of bladder cancer patients treated with immune checkpoint inhibitors. Cancer Rep (Hoboken). 2018 06; 1(1):e1002.
Score: 0.100
-
Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of bladder carcinoma. J Immunother Cancer. 2017 08 15; 5(1):68.
Score: 0.096
-
Safety and Efficacy of Durvalumab (MEDI4736), an Anti-Programmed Cell Death Ligand-1 Immune Checkpoint Inhibitor, in Patients With Advanced Urothelial Bladder Cancer. J Clin Oncol. 2016 09 10; 34(26):3119-25.
Score: 0.088
-
Whole-exome sequencing of muscle-invasive bladder cancer identifies recurrent mutations of UNC5C and prognostic importance of DNA repair gene mutations on survival. Clin Cancer Res. 2014 Dec 15; 20(24):6605-17.
Score: 0.079
-
Critical analysis of contemporary clinical research in muscle-invasive and metastatic urothelial cancer: a report from the Bladder Cancer Advocacy Network Clinical Trials Working Group. Cancer. 2013 Jun 01; 119(11):1994-8.
Score: 0.070
-
12th Annual meeting of the Society of Urologic Oncology (SUO) bladder cancer sessions I and II summary report. Urol Oncol. 2012 Nov-Dec; 30(6):944-7.
Score: 0.069
-
Health-related Quality of Life in Patients with Previously Treated Advanced Urothelial Carcinoma from EV-301: A Phase 3 Trial of Enfortumab Vedotin Versus Chemotherapy. Eur Urol. 2024 Jun; 85(6):574-585.
Score: 0.038